tailieunhanh - báo cáo khoa học: "Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials | Cuppone et al. Journal of Experimental Clinical Cancer Research 2011 30 54 http content 30 1 54 Journal of Experimental Clinical Cancer Research RESEARCH Open Access Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients Meta-regression analysis of randomized trials 1 f f 13 1 4 Federica Cuppone Emilio Bria Vanja Vaccaro Fabio Puglisi Alessandra Fabi Isabella Sperduti 111 11 1 Paolo Carlini Michele Milella Cecilia Nisticò Michelangelo Russillo Paola Papaldo Gianluigi Ferretti Matti Aapro5 Diana Giannarelli4 and Francesco Cognetti1 Abstract Background Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile. Methods A literature-based meta-analysis to quantify the magnitude of benefit and safety of adding bevacizumab to chemotherapy for advanced breast cancer patients was conducted. Meta-regression and sensitivity analyses were also performed to identify additional predictors of outcome and to assess the influence of trial design. Results Five trials 3 841 patients were gathered. A significant interaction according to treatment line was found for progression-free survival PFS p PFS was significantly improved for 1st line Hazard Ratio HR p with a 1-yr absolute difference AD of number needed to treat NNT 12 . A non-significant trend was found in overall survival OS and in PFS for 2nd line. Responses were improved with the addition of bevacizumab without interaction between 1st line Relative Risk RR p and 2nd line RR p . The most important toxicity was hypertension accounting for a significant AD of against bevacizumab number needed to harm NNH 22 . Other significant although less clinically meaningful adverse events were proteinuria neurotoxicity febrile neutropenia and bleeding.